Table 1 Demographic, clinical and histopathological data of the patients, and comparison of these data according to the control and study groups
Total (N = 72) | Control Group (n = 39) | Study Group (n = 33) | P value | |
|---|---|---|---|---|
Gender, N (%) | 0.456 | |||
Male | 64 (89.9) | 36 (92.3) | 28 (84.8) | |
Female | 8 (11.1) | 3 (7.7) | 5 (15.2) | |
Age, \(\bar x\) (Min-Max) | 61 (20–84) | 63 (41–84) | 59 (20–77) | 0.078 |
Smoking, N (%) | 63 (87.5) | 35 (89.7) | 28 (84.8) | 0.723 |
Location, N (%) | 0.175 | |||
Right Lung, | ||||
superior lob | 29 (40.3) | 15 (38.5) | 14 (42.4) | |
median lob | 3 (4.2) | 2 (5.1) | 1 (3.0) | |
inferior lob | 8 (11.1) | 6 (15.4) | 2 (6.1) | |
Left Lung, | ||||
superior lob | 23 (31.9) | 12 (30.8) | 11 (33.3) | |
inferior lob | 9 (12.5) | 4 (10.2) | 5 (15.2) | |
Preoperative diagnostic method, N (%) | 0.719 | |||
Aspiration | 29 (40.3) | 14 (35.9) | 15 (45.5) | |
Biopsy | 43 (59.7) | 25 (64.1) | 18 (54.5) | |
SUV value with CT-PET | 0.530 | |||
<5 | 6 (8.3) | 5 (12.8) | 1 (3.0) | |
5–10 | 15 (20.8) | 7 (17.9) | 8 (24.2) | |
10–15 | 25 (34.7) | 14 (35.9) | 11 (33.3) | |
15–20 >20 | 18 (25.0) 8 (11.1) | 10 (25.6) 3 (7.7) | 8 (24.2) 5 (15.2) | |
Surgery type, N (%) | 0.084 | |||
Lobectomy | 44 (61.1) | 29 (74.4) | 15 (45.5) | |
Bilobectomy | 5 (6.9) | 2 (5.1) | 3 (9.1) | |
Segmentectomy | 4 (5.6) | 1 (2.6) | 3 (9.1) | |
Pneumonectomy | 19 (26.4) | 7 (17.9) | 12 (36.4) | |
Tumor subtype, N (%) | 0.064 | |||
Adenocarcinoma | 33 (45.8) | 19 (48.7) | 14 (42.2) | |
SCC | 29 (40.3) | 18 (46.2) | 11 (33.3) | |
NSCLC | 10 (13.9) | 2 (5.1) | 8 (24.2) | |
TNM Stage, N (%) | 0.004 | |||
Stage 1 | 25 (34.7) | 16 (41.0) | 9 (27.3) | |
Stage 2 | 23 (31.9) | 13 (33.3) | 10 (30.3) | |
Stage 3 | 10 (13.9) | 8 (20.5) | 2 (6.1) | |
Stage 4 | 14 (19.4) | 2 (5.1) | 12 (36.4) | |
Tumor Diameter (mm) \(\bar x\) (Min-Max) | 40.0 (7.0–80.0) | 35 (13.0–80.0) | 40 (7.0–73.0) | 0.317 |
Lymph node metastasis, N (%) | 29 (40.3) | 15 (38.4) | 14 (42.4) | 0.432 |
Pleural invasion, N (%) | 11 (15.3) | 6 (15.4) | 5 (45.5) | 1.000 |
Lymphovascular invasion, N (%) | 14 (19.4) | 9 (23.1) | 5 (15.2) | 0.584 |
Fibrosis, N (%) | 51 (70.8) | 23 (59.0) | 28 (84.8) | 0.032 |
Necrosis, N (%) | 42 (58.3) | 25 (64.1) | 17 (51.5) | 0.401 |
Foreign body reaction, N (%) | 11 (15.3) | 0 (0.0) | 11 (33.3) | 0.000 |
Degree of inflammation, N (%) | 0.000 | |||
Mild | 27 (37.5) | 16 (41.0) | 11 (33.3) | |
Moderate Severe | 27 (37.5) 18 (25.0) | 20 (51.3) 3 (7.7) | 7 (21.2) 15 (45.5) | |
CD4 + T lymphocyte, \(\bar x\) (Min-Max) | 0.012 0.233 | |||
Intratumoral | 17 (0-220) | 22 (0–87) | 11 (2-220) | |
Peritumoral | 158.5 (1-405) | 157 (1-357) | 214 (22–405) | |
P value | < 0.0001 | < 0.0001 | < 0.0001 | |
CD8 + T lymphocyte, \(\bar x\) (Min-Max) | ||||
Intratumoral | 18 (2-180) | 21 (4-180) | 18 (2-131) | 0.635 |
Peritumoral | 95 (12–374) | 157 (1-357) | 127 (12–374) | 0.156 |
P value | < 0.0001 | < 0.0001 | < 0.0001 | |
CD4/CD8 ratio, \(\bar x\) (Min-Max) | ||||
Intratumoral | 0.87 (0-7.12) | 1.33 (0.0-7.13) | 0.77 (0.11–2.67) | 0.016 |
Peritumoral | 1.49 (0.03–11.42) | 1.50 (0.03–11.42) | 1.46 (0.18–6.50) | 0.079 |
P value | 0.001 | 0.113 | 0.0014 | |
Radiotherapy, N (%) | 24 (33.3) | 12 (30.8) | 12 (36.4) | 0.802 |
Survival, X ± SD (month) | 52.3 ± 4.1 | 48.9 ± 3.4 | 57.1 ± 5.2 | 0.501 |
Relapse, N (%) | 12 (16.7) | 6 (15.4) | 6 (18.2) | 1.000 |
Distant Organ Metastasis, N (%) | 10 (13.9) | 4 (10.3) | 6 (18.2) | 0.496 |